Evidence map›Paper›PMID 42528764›Full record

ArticleFrontiers in oncology2026

Exploratory analysis of tumor budding density in resected synchronous and metachronous colorectal liver metastases.

Nemanja Petrović, Biljana Kukić, Nenad Šolajić, Nemanja Maletin, Ivana Kolarov Bjelobrk, Jelena Radić, Aleksandar Đermanović, Ivan Nikolić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nemanja PetrovićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Biljana KukićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Nenad ŠolajićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Nemanja MaletinFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Ivana Kolarov BjelobrkFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Jelena RadićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Aleksandar ĐermanovićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Ivan NikolićFaculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tumor budding is an adverse histopathological feature in colorectal cancer, but its role in colorectal liver metastases (CRLM) remains insufficiently defined. This study explored the association between tumor budding density and clinical outcomes in resected synchronous and metachronous CRLM. Methods: This single-center ambispective cohort included 77 patients who underwent R0 resection of CRLM between 2007 and 2017. Tumor budding density was assessed in liver metastases and classified as low (0-9 buds per field) or high (≥10 buds per field). Outcomes were analyzed according to tumor budding density, metastatic timing, and preoperative regimen. Results: Forty-one patients had synchronous and 36 had metachronous CRLM. Overall, 64 patients received preoperative systemic therapy, including FOLFOX4 in 38 and FOLFOX4 plus bevacizumab in 26. Low tumor budding density was associated with better 2-year overall survival in synchronous CRLM, both in the pooled cohort (95.2% vs. 65.0%, p = 0.015) and in patients treated with FOLFOX4 (90.9% vs. 55.6%, p = 0.049) or FOLFOX4 plus bevacizumab (100.0% vs. 66.7%, p = 0.048). No significant association was observed in metachronous CRLM. Kaplan-Meier analyses of time to progression and 5-year overall survival did not show significant differences by tumor budding density. Conclusion: Tumor budding density showed an exploratory association with 2-year overall survival in patients with synchronous resected colorectal liver metastases, but this association was not consistently observed in metachronous disease or in long-term time-to-event analyses. These findings suggest that tumor budding may reflect aggressive metastatic biology, but larger standardized studies are required before it can be considered an independent prognostic marker.

Indexed as

colorectal cancercolorectal liver metastaseshistopathological responsemetachronous metastasesprognosissurvivalsynchronous metastasestumor budding

Identifiers

PMID42528764
PMCPMC13414808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.